

Lucia Del Mastro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6963232/publications.pdf>

Version: 2024-02-01

333
papers

12,528
citations

30070

54
h-index

31849

101
g-index

339
all docs

339
docs citations

339
times ranked

11300
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 269-275.	2.5	24
2	Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate. <i>Annals of Oncology</i> , 2022, 33, 347-349.	1.2	16
3	Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 400-408.	6.3	15
4	Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. <i>Tumori</i> , 2022, , 030089162110675.	1.1	1
5	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	5.2	17
6	Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. <i>Lancet Oncology</i> , The, 2022, 23, 382-392.	10.7	107
7	Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2022, 37, 954-968.	0.9	41
8	Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100198.	3.0	0
9	Definition of High-Risk Early Hormone-Positive HER2 ⁺ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
10	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	3.7	21
11	Circulating miRNAs in Breast Cancer Diagnosis and Prognosis. <i>Cancers</i> , 2022, 14, 2317.	3.7	16
12	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	6.3	3
13	Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. <i>ESMO Open</i> , 2022, 7, 100483.	4.5	3
14	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
15	Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6320.	4.1	4
16	Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 241-250.	2.4	6
17	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	5.2	13
18	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17

#	ARTICLE	IF	CITATIONS
19	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	7.0	4
20	Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI). <i>ESMO Open</i> , 2021, 6, 100054.	4.5	7
21	T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. <i>ESMO Open</i> , 2021, 6, 100099.	4.5	12
22	COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the beginning of the first pandemic wave?. <i>ESMO Open</i> , 2021, 6, 100100.	4.5	7
23	Multigene tests for breast cancer: the physician's perspective. <i>Oncotarget</i> , 2021, 12, 936-947.	1.8	9
24	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	5.2	6
25	The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690320.	2.8	23
26	Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, e303-e313.	10.7	116
27	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	1.6	70
28	Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103365.	4.4	48
29	Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 994-1004.	1.2	393
30	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	10.7	147
31	First Surgical National Consensus Conference of the Italian Breast Surgeons association (ANISC) on breast cancer management in neoadjuvant setting: Results and summary. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1913-1919.	1.0	3
32	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
33	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	10.7	41
34	Diversity of Cardiologic Issues in a Contemporary Cohort of Women With Breast Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 654728.	2.4	5
35	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. <i>Annals of Oncology</i> , 2021, 32, 1571-1581.	1.2	225
36	De novo metastatic breast cancer arising in young women: review of the current evidence. <i>Clinical Breast Cancer</i> , 2021, , .	2.4	6

#	ARTICLE	IF	CITATIONS
37	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021, 11, e049128.	1.9	12
38	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110534.	3.2	5
39	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	1.4	0
40	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1258-1267.	1.6	33
41	Tamoxifen Exposure during Pregnancy: A Systematic Review and Three More Cases. <i>Breast Care</i> , 2020, 15, 148-156.	1.4	32
42	Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	5.1	12
43	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e181-e187.	2.4	30
44	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	2.4	5
45	Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study. <i>ESMO Open</i> , 2020, 5, e000719.	4.5	5
46	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	1.6	69
47	Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. <i>ESMO Open</i> , 2020, 5, e000979.	4.5	2
48	Body weight and return to work among survivors of early-stage breast cancer. <i>ESMO Open</i> , 2020, 5, e000908.	4.5	9
49	Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 574669.	2.8	48
50	Update on the Management of Breast Cancer during Pregnancy. <i>Cancers</i> , 2020, 12, 3616.	3.7	37
51	Call for ensuring cancer care continuity during COVID-19 pandemic. <i>ESMO Open</i> , 2020, 5, e000783.	4.5	31
52	95TiP Gruppo Italiano Mammella (GIM) 10 - CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC). <i>Annals of Oncology</i> , 2020, 31, S47.	1.2	0
53	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59
54	Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13315.	3.4	28

#	ARTICLE	IF	CITATIONS
55	Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study. <i>British Journal of Cancer</i> , 2020, 122, 1611-1617.	6.4	12
56	11P BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC). <i>Annals of Oncology</i> , 2020, 31, S20.	1.2	1
57	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	2.8	6
58	Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities. <i>JCO Oncology Practice</i> , 2020, 16, e1304-e1314.	2.9	38
59	Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4364.	4.1	4
60	Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. <i>Journal of Oncology</i> , 2020, 2020, 1-10.	1.3	4
61	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. <i>Breast</i> , 2020, 52, 23-32.	2.2	15
62	Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. <i>Cancer Research</i> , 2020, 80, GS3-04-GS3-04.	0.9	90
63	Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046). , 2020, , .		5
64	Abstract P4-14-01: Modulation of tumor infiltrating lymphocytes (TILs) by palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ patients (pts) enrolled in the Michelangelo NA-PHER2 trial. , 2020, , .		0
65	Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2019, 111, 86-94.	6.3	73
66	Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. <i>Clinical Medicine Insights Reproductive Health</i> , 2019, 13, 117955811986458.	3.9	20
67	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0.784314 rgBT /Ov 1137.	3.7	22
68	Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: An exploratory analysis of the GIM2 trial. <i>Annals of Oncology</i> , 2019, 30, v61.	1.2	0
69	Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study. <i>Annals of Oncology</i> , 2019, 30, v113.	1.2	0
70	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131
71	The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial. <i>Annals of Oncology</i> , 2019, 30, iii28.	1.2	1
72	Dose-dense adjuvant chemotherapy in early breast cancer: 15-year results of the phase III Mammella InterGruppo (MIG)-1 study. <i>Annals of Oncology</i> , 2019, 30, iii27.	1.2	1

#	ARTICLE	IF	CITATIONS
73	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBEO phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186.	2.8	39
74	Reply to V. Turan et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 86-88.	1.6	6
75	Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 105-114.	1.6	72
76	Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. <i>Breast Journal</i> , 2019, 25, 444-449.	1.0	6
77	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	13.7	260
78	New emerging targets in cancer immunotherapy: the role of GITR. <i>ESMO Open</i> , 2019, 4, e000738.	4.5	40
79	Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6045.	4.1	15
80	T-DM1 EFFICACY AND ACTIVITY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PROGRESSING AFTER FRONTLINE TAXANE PLUS PERTUZUMAB AND TRASTUZUMAB: AN ITALIAN MULTICENTER OBSERVATIONAL STUDY OF THE GRUPPO ITALIANO MAMMELLA (GIM) STUDY GROUP. <i>Breast</i> , 2019, 48, S45.	2.2	0
81	Fertility, sexuality and cancer in young adult women. <i>Current Opinion in Oncology</i> , 2019, 31, 259-267.	2.4	20
82	Role of dose-dense chemotherapy in high-risk early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 480-485.	2.4	4
83	Increases in Tumor N-Glycan Polylactosamines Associated with Advanced HER2-Positive and Triple-Negative Breast Cancer Tissues. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800014.	1.6	50
84	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	7.7	88
85	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	2.4	29
86	Reply to the letter "Safety of fertility preservation in women with breast cancer". <i>Breast</i> , 2019, 43, 149-150.	2.2	1
87	Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers "ESEMPIO study. <i>Future Oncology</i> , 2019, 15, 33-44.	2.4	18
88	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. <i>Cancer Treatment Reviews</i> , 2019, 72, 65-77.	7.7	83
89	Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM). <i>Journal of Clinical Oncology</i> , 2019, 37, 504-504.	1.6	10
90	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study. <i>Journal of Clinical Oncology</i> , 2019, 37, 527-527.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study.. Journal of Clinical Oncology, 2019, 37, e12507-e12507.	1.6	2
92	Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)â€“negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxel. , 2019, , .		0
93	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2019, 37, e12528-e12528.	1.6	0
94	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 474-485.	10.7	59
95	Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence. Blood Purification, 2018, 46, 56-69.	1.8	5
96	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. Breast, 2018, 40, 45-52.	2.2	4
97	The BCY3/BCC 2017 survey on physiciansâ€™ knowledge, attitudes and practice towards fertility and pregnancy issues in young breast cancer patients. European Journal of Cancer, 2018, 92, S22.	2.8	1
98	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncology, The, 2018, 19, 249-256.	10.7	130
99	Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 62, 123-132.	7.7	16
100	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. Breast, 2018, 37, 142-147.	2.2	29
101	Overweight, obesity and weight gain after breast cancer (BC): A prospective clinical study. Annals of Oncology, 2018, 29, viii620-viii621.	1.2	0
102	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patientâ€™Level Data. Journal of Clinical Oncology, 2018, 36, 1981-1990.	1.6	268
103	Physiciansâ€™ knowledge, attitudes and practice towards fertility and pregnancy-related issues in BRCA-mutated breast cancer (BC) patients (pts): Results from the BCY3/BCC 2017 survey. Annals of Oncology, 2018, 29, viii606.	1.2	0
104	Weight loss, physical and psychological patient reported outcomes (PROs) among obese patients (pts) with early breast cancer (BC). Annals of Oncology, 2018, 29, viii621.	1.2	0
105	Management of young women with early breast cancer. ESMO Open, 2018, 3, e000458.	4.5	15
106	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. Frontiers in Oncology, 2018, 8, 608.	2.8	160
107	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. BMC Cancer, 2018, 18, 932.	2.6	6
108	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	2.2	75

#	ARTICLE	IF	CITATIONS
109	Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. <i>Breast</i> , 2018, 41, 51-56.	2.2	41
110	Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2018, 3, e000361.	4.5	49
111	Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2018, 29, 1497-1508.	1.2	305
112	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). <i>European Journal of Cancer</i> , 2018, 99, 9-19.	2.8	10
113	Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. <i>Cancer Treatment Reviews</i> , 2018, 68, 102-110.	7.7	183
114	Abstract GS1-01: Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials. <i>Cancer Research</i> , 2018, 78, GS1-01-GS1-01.	0.9	18
115	PARP inhibitors (PARPi) for the treatment of BRCA-mutated HER2-negative (HER2-) metastatic breast cancer (MBC) patients: A systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, e13098-e13098.	1.6	1
116	First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study. <i>Journal of Clinical Oncology</i> , 2018, 36, e13032-e13032.	1.6	0
117	Platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): A systematic review and meta-analysis of randomized controlled trials (RCTs). <i>Journal of Clinical Oncology</i> , 2018, 36, 595-595.	1.6	1
118	Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1137-1138.	1.6	2
119	Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 4.	3.0	17
120	Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 47-59.	0.6	13
121	Pharmacotherapy to protect ovarian function and fertility during cancer treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 739-742.	1.8	9
122	State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature. <i>Cancer Treatment Reviews</i> , 2017, 57, 50-57.	7.7	47
123	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 601-610.e2.	2.4	30
124	Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. <i>Breast</i> , 2017, 33, 104-108.	2.2	16
125	Efficacy and safety of eribulin in taxane-refractory patients in the "real world". <i>Future Oncology</i> , 2017, 13, 971-978.	2.4	13
126	A survey on physicians' knowledge, practice and attitudes on fertility and pregnancy issues in young breast cancer patients. <i>Breast</i> , 2017, 32, S85-S86.	2.2	4

#	ARTICLE	IF	CITATIONS
127	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39
128	Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. <i>European Journal of Cancer</i> , 2017, 71, 25-33.	2.8	79
129	Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 804-805.	1.6	20
130	Fertility and pregnancy issues in BRCA -mutated breast cancer patients. <i>Cancer Treatment Reviews</i> , 2017, 59, 61-70.	7.7	68
131	Luteinizing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1357-1362.	1.8	5
132	Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?. <i>Annals of Oncology</i> , 2017, 28, 1683-1685.	1.2	10
133	Adverse Events (AE) of Targeted Agents Added to Endocrine Therapy in Patients with Hormone Receptor-positive Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. <i>Breast</i> , 2017, 36, S43-S44.	2.2	0
134	The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. <i>BMC Cancer</i> , 2017, 17, 346.	2.6	30
135	A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice. <i>JAMA Oncology</i> , 2017, 3, 735.	7.1	0
136	NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study. <i>Breast</i> , 2017, 36, S51-S52.	2.2	0
137	Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study. <i>Annals of Oncology</i> , 2017, 28, v83-v84.	1.2	1
138	Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study. <i>Oncotarget</i> , 2017, 8, 44800-44810.	1.8	4
139	A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer. <i>Annals of Oncology</i> , 2017, 28, vi25.	1.2	0
140	The Pregnancy and Fertility (PREFER) study: a prospective cohort study on fertility-preserving (FP) strategies in young early breast cancer (EBC) patients (pts). <i>Annals of Oncology</i> , 2017, 28, vi26.	1.2	0
141	Long-Term Follow-Up of the Intergroup Exemestane Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2507-2514.	1.6	22
142	Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study. <i>Cancer Research</i> , 2017, 77, P4-21-39-P4-21-39.	0.9	4
143	Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 515-515.	1.6	3
144	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients. <i>Minerva Obstetrics and Gynecology</i> , 2017, 69, 350-356.	1.0	3

#	ARTICLE	IF	CITATIONS
145	Abstract P5-15-07: First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational "GIM-13" AMBRA-Italian study. , 2017, , .		0
146	Abstract P1-09-12: Dose dense adjuvant chemotherapy in patients with early breast cancer: Differential treatment effects according to composite index of benefit. , 2017, , .		0
147	Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 1057-1057.	1.6	1
148	The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.. Journal of Clinical Oncology, 2017, 35, 1055-1055.	1.6	1
149	Trastuzumab-related cardiotoxicity in patients with non-limiting cardiac comorbidity.. Journal of Clinical Oncology, 2017, 35, e12043-e12043.	1.6	0
150	Characteristics of disease activity able to identify risk categories and probability to respond to first-line endocrine therapy (ET) in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts): Dream or reality? Evaluation of a composite risk score in a subgroup population of the GIM 13-AMBRA study.. Journal of Clinical Oncology, 2017, 35, 1049-1049.	1.6	39
151	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients: an international multicentre hospital-based retrospective cohort study. Annals of Oncology, 2016, 27, vi49.	1.2	0
152	Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study. Annals of Oncology, 2016, 27, iv70.	1.2	0
153	The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy. Annals of Oncology, 2016, 27, iv64.	1.2	0
154	The effect of financial difficulties on clinical outcomes in Italian cancer patients: a pooled analysis of 16 academic prospective clinical trials. Annals of Oncology, 2016, 27, iv111.	1.2	0
155	health economics The effect of financial difficulties on clinical outcomes in Italian cancer patients: A pooled analysis of 16 academic prospective clinical trials. Annals of Oncology, 2016, 27, vi572.	1.2	0
156	The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Annals of Oncology, 2016, 27, 2224-2229.	1.2	103
157	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. Cancer Treatment Reviews, 2016, 46, 20-26.	7.7	87
158	Treatment with aromatase inhibitors and markers of cardiovascular disease. Breast Cancer Research and Treatment, 2016, 160, 261-267.	2.5	7
159	Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients. Expert Review of Clinical Pharmacology, 2016, 9, 1153-1161.	3.1	8
160	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treatment Reviews, 2016, 49, 65-76.	7.7	167
161	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. British Journal of Cancer, 2016, 115, 1471-1478.	6.4	45
162	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. Tumori, 2016, 102, 108-113.	1.1	4

#	ARTICLE	IF	CITATIONS
163	TP53 germline mutation testing in early onset breast cancer. <i>Annals of Oncology</i> , 2016, 27, iv71.	1.2	0
164	Reply to the letter to the editor "Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?" by Rodriguez-Wallberg et al.. <i>Annals of Oncology</i> , 2016, 27, 548-549.	1.2	8
165	Fertility preservation in BRCA-mutated breast cancer patients. <i>Breast Cancer Management</i> , 2016, 5, 61-68.	0.2	6
166	News on the medical treatment of young women with early-stage HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1643-1655.	1.8	8
167	Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?. <i>European Journal of Cancer</i> , 2016, 54, 163-164.	2.8	3
168	5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 117-126.	2.5	12
169	Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 211-218.	2.4	11
170	Cancer and fertility preservation: international recommendations from an expert meeting. <i>BMC Medicine</i> , 2016, 14, 1.	5.5	521
171	New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients. <i>Cancer Treatment Reviews</i> , 2016, 42, 18-23.	7.7	11
172	Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial. <i>Supportive Care in Cancer</i> , 2016, 24, 1285-1294.	2.2	17
173	Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 529-529.	1.6	0
174	1849 Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPIO study. <i>European Journal of Cancer</i> , 2015, 51, S281-S282.	2.8	0
175	1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies. <i>European Journal of Cancer</i> , 2015, 51, S318-S319.	2.8	1
176	1863 First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab. <i>European Journal of Cancer</i> , 2015, 51, S286.	2.8	0
177	PO62 FIRST LINE TRASTUZUMAB-BASED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PRESENTING WITH DE NOVO OR RECURRENT DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY. <i>Breast</i> , 2015, 24, S43.	2.2	0
178	Correlation between treatment with aromatase inhibitors and carotid intima-media thickness, carotid stenosis and abdominal aortic diameter. A prospective cohort study. <i>Annals of Oncology</i> , 2015, 26, vi10.	1.2	0
179	First line trastuzumab-based therapy in her2-positive metastatic breast cancer patients presenting with de novo or recurrent disease. <i>Annals of Oncology</i> , 2015, 26, vi10.	1.2	0
180	Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. <i>Journal of Translational Medicine</i> , 2015, 13, 324.	4.4	40

#	ARTICLE	IF	CITATIONS
181	Temporary Ovarian Suppression With Gonadotropinâ€Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?. <i>Oncologist</i> , 2015, 20, 1233-1235.	3.7	38
182	1861 Body mass index and prognosis in HER2-positive metastatic breast cancer patients. <i>European Journal of Cancer</i> , 2015, 51, S285-S286.	2.8	0
183	Protecting Ovaries During Chemotherapy Through Gonad Suppression. <i>Obstetrics and Gynecology</i> , 2015, 126, 901.	2.4	19
184	Progesterone Receptor Status and Clinical Outcome in Breast Cancer Patients with Estrogen Receptor-Positive Locoregional Recurrence. <i>Tumori</i> , 2015, 101, 398-403.	1.1	5
185	A meta-analysis on impact of age at first pregnancy on the risk of developing breast cancer according to subtype. <i>Annals of Oncology</i> , 2015, 26, vi5.	1.2	0
186	Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: a systematic review and meta-analysis of randomized studies. <i>Annals of Oncology</i> , 2015, 26, vi2.	1.2	0
187	Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (PREgnancy and FERtility) trial. <i>Annals of Oncology</i> , 2015, 26, vi10.	1.2	0
188	The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer. <i>Annals of Oncology</i> , 2015, 26, vi8.	1.2	1
189	Outcomes of hormone-responsive (HR+) HER2 negative (HER2-) metastatic breast cancer (MBC) patients (P) according to their starting first-line (1st) treatment (T): chemotherapy (CT) or hormonal therapy (HT). <i>Annals of Oncology</i> , 2015, 26, vi11.	1.2	0
190	Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2632.	7.4	180
191	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy as a strategy to reduce ovarian failure in early breast cancer patients. <i>Annals of Oncology</i> , 2015, 26, vi1.	1.2	28
192	Exploring the safety of chemotherapy for treating breast cancer during pregnancy. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1395-1408.	2.4	18
193	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2â€ˆˆ2 factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1863-1872.	13.7	164
194	Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1799-1817.	3.1	16
195	Pharmacokinetics of Trastuzumab in Haemodialysis. <i>Breast Journal</i> , 2015, 21, 329-331.	1.0	6
196	Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. <i>Annals of Oncology</i> , 2015, 26, 2408-2419.	1.2	178
197	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254.	2.4	1
198	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. <i>Oncologist</i> , 2015, 20, 880-889.	3.7	26

#	ARTICLE	IF	CITATIONS
199	A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPIo study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11539-e11539.	1.6	3
200	First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11575-e11575.	1.6	0
201	Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole. <i>British Journal of Cancer</i> , 2014, 110, 1133-1138.	6.4	10
202	Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients. <i>Endocrine-Related Cancer</i> , 2014, 21, R51-R65.	3.1	35
203	A risk score model predictive of the presence of additional disease in the axilla in early-breast cancer patients with one or two metastatic sentinel lymph nodes. <i>European Journal of Surgical Oncology</i> , 2014, 40, 835-842.	1.0	17
204	The five "W"s for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 112-128.	4.4	87
205	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	7.4	25
206	Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases. <i>Annals of Oncology</i> , 2014, 25, 912-913.	1.2	28
207	Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4557-4561.	3.7	14
208	Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 675-683.	7.7	169
209	OR30 Prospective study of fertility preservation strategies in young early breast cancer patients: the PREFER (pregnancy and fertility) trial. <i>Breast</i> , 2014, 23, S12.	2.2	0
210	Follow-up of patients with early breast cancer: Is it time to rewrite the story?. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 130-141.	4.4	36
211	Long-term outcome results of the phase III PROMISE-GIM6 study evaluating the role of LHRH analog (LHRHa) during chemotherapy (CT) as a strategy to reduce ovarian failure in early breast cancer (BC) patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 105-105.	1.6	8
212	Pegfilgrastim (P) administration after 24, 72, or 96 hours (h) to allow dose-dense (DD) anthracycline- and taxane-based chemotherapy (CT) in breast cancer (BC) patients (pts): A single-center experience within the GIM2 randomized phase III study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9632-9632.	1.6	0
213	Fertility issues in young breast cancer patients: what women want. <i>Journal of Thoracic Disease</i> , 2014, 6, 584-8.	1.4	3
214	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013, 13, 164.	2.6	19
215	Anthracycline-free therapy for HER2 -amplified breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, 1037-1038.	10.7	1
216	Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 167-174.	2.5	19

#	ARTICLE	IF	CITATIONS
217	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013, 22, 470-475.	2.2	13
218	Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120.	2.2	73
219	Doseâ€Dense FEC Followed by Doseâ€Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. <i>Oncologist</i> , 2013, 18, 924-925.	3.7	0
220	Doseâ€Dense FEC Followed by Doseâ€Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. <i>Oncologist</i> , 2013, 18, 1149-1149.	3.7	0
221	Trastuzumab emtansine in the treatment of <i>HER-2</i>-positive metastatic breast cancer patients. <i>Future Oncology</i> , 2013, 9, 955-957.	2.4	10
222	Abstract S5-06: Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the gruppo Italiano mammella (GIM)-2 randomized phase III study. , 2013, , .		7
223	Fertility counseling of young breast cancer patients. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S68-80.	1.4	16
224	Abstract P2-16-10: Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer. , 2013, , .		0
225	HM35 Role of temporary ovarian suppression obtained with GnRH analogue in reducing premature ovarian failure induced by chemotherapy in premenopausal cancer patients: a meta-analysis of randomized studies. <i>Breast</i> , 2012, 21, S13.	2.2	1
226	Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. <i>BMC Cancer</i> , 2012, 12, 216.	2.6	6
227	Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1391-1405.	2.4	19
228	Pertuzumab and Trastuzumab in Combination with Vinorelbine for First-Line Treatment of Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (LABC/MBC): A Single-Arm, Two-Cohort, Phase II Study (Velvet). <i>Annals of Oncology</i> , 2012, 23, ix142.	1.2	1
229	Role of Temporary Ovarian Suppression Obtained with GNRH Analog in Reducing Premature Ovarian Failure (POF) Induced By Chemotherapy in Premenopausal Cancer Patients: a Meta-Analysis of Randomized Studies. <i>Annals of Oncology</i> , 2012, 23, ix501.	1.2	0
230	Fertility Preservation in Young Early Breast Cancer: Strategies and Patient Preferences. <i>Annals of Oncology</i> , 2012, 23, ix521.	1.2	0
231	Incidence of Hepatitis B and C Infections in Early Breast Cancer Patients and Impact on Systemic Treatments. <i>Annals of Oncology</i> , 2012, 23, ix454.	1.2	0
232	Stevens-Johnson syndrome after treatment with bendamustine. <i>Leukemia Research</i> , 2012, 36, e153-e154.	0.8	11
233	Medical approaches to preservation of fertility in female cancer patients. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 387-396.	1.8	35
234	Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: Current role and future perspectives. <i>Cancer Treatment Reviews</i> , 2011, 37, 208-211.	7.7	15

#	ARTICLE	IF	CITATIONS
235	Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes. <i>European Journal of Surgical Oncology</i> , 2011, 37, 688-694.	1.0	44
236	Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more â€¦. <i>Breast</i> , 2011, 20, 1-6.	2.2	57
237	Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1303-1313.	2.4	10
238	Gonadotropin-Releasing Hormone Analogue for Premenopausal Women With Breast Cancerâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1760.	7.4	3
239	Effect of the Gonadotropin-Releasing Hormone Analogue Triptorelin on the Occurrence of Chemotherapy-Induced Early Menopause in Premenopausal Women With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 269-76.	7.4	311
240	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1529-1539.	6.3	27
241	Temporary Ovarian Suppression With Goserelin and Ovarian Function Protection in Patients With Breast Cancer Undergoing Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 3339-3340.	1.6	4
242	Letrozole withdrawal response in locally advanced breast cancer. <i>Annals of Oncology</i> , 2011, 22, 1927-1928.	1.2	3
243	Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.. <i>Journal of Clinical Oncology</i> , 2011, 29, 515-515.	1.6	1
244	A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. <i>Breast</i> , 2010, 19, 333-338.	2.2	33
245	Use in current clinical practice of 70-gene signature in early breast cancer. <i>International Journal of Cancer</i> , 2010, 127, 2736-2737.	5.1	2
246	Estrone Sulphate, FSH, and Testosterone Levels in Two Male Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Oncologist</i> , 2010, 15, 1270-1272.	3.7	13
247	Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. <i>Annals of Oncology</i> , 2010, 21, 2029-2039.	1.2	8
248	Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1237-1242.	1.2	29
249	Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?. <i>Annals of Oncology</i> , 2010, 21, 1376-1377.	1.2	1
250	Single-nucleotide polymorphisms (SNPs) of CYP19A1 and plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2606-2606.	1.6	1
251	Role of luteinizing hormone-releasing hormone analog (LHRHa) triptorelin (T) in preserving ovarian function during chemotherapy for early breast cancer patients: Results of a multicenter phase III trial of Gruppo Italiano Mammella (GIM) group.. <i>Journal of Clinical Oncology</i> , 2010, 28, 528-528.	1.6	13
252	Abstract P1-11-20: Open-Label Phase II Study of Neoadjuvant Bevacizumab Combined with FECâ€™Paclitaxel in Patients with Inflammatory or Locally Advanced Breast Cancer. , 2010, , .		0

#	ARTICLE	IF	CITATIONS
253	Reply to A. Snchez-Muoz et al. Journal of Clinical Oncology, 2009, 27, e257-e258.	1.6	0
254	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2566-2567.	1.6	10
255	Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and 2-microglobulin downregulation in breast cancer. Human Immunology, 2009, 70, 492-495.	2.4	12
256	Plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment: Association with single nucleotide polymorphisms (SNPs) of CYP19A1. Journal of Clinical Oncology, 2009, 27, 555-555.	1.6	3
257	Anti-Mullerian hormone (AMH) and ovarian function in young breast cancer (BC) women receiving adjuvant chemotherapy (CT). Journal of Clinical Oncology, 2009, 27, e11544-e11544.	1.6	1
258	Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial. Journal of Clinical Oncology, 2008, 26, 1972-1979.	1.6	133
259	Hexaprimer Amplification Refractory Mutation System PCR for Simultaneous Single-Tube Genotyping of 2 Close Polymorphisms. Clinical Chemistry, 2008, 54, 227-229.	3.2	9
260	The difficult decision-making process for using or not using adjuvant chemotherapy in premenopausal endocrine-responsive breast cancer patients. Annals of Oncology, 2008, 19, 1213-1215.	1.2	1
261	Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-OvestMammella Intergruppo (GONO-MIG) Group. Annals of Oncology, 2008, 19, 299-307.	1.2	18
262	Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC). Journal of Clinical Oncology, 2008, 26, 1034-1034.	1.6	2
263	Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: A randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group. Journal of Clinical Oncology, 2008, 26, 516-516.	1.6	6
264	Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. Journal of Clinical Oncology, 2007, 25, 486-492.	1.6	835
265	Re: Acute Myeloid Leukemia or Myelodysplastic Syndrome Following Use of Granulocyte Colony-Stimulating Factors During Breast Cancer Adjuvant Chemotherapy. Journal of the National Cancer Institute, 2007, 99, 1050-1051.	6.3	3
266	Reducing the risk of distant metastases in breast cancer patients: Role of aromatase inhibitors. Cancer Treatment Reviews, 2007, 33, 681-687.	7.7	11
267	Survival and safety of exemestane versus tamoxifen after 23 years' tamoxifen treatment (Intergroup) Tj ETQq1 1.0,784314 rgBT /Ov 13.7 805	1.0,784314	805
268	Role of colony stimulating factors (CSFs) in solid tumours: Results of an expert panel. Critical Reviews in Oncology/Hematology, 2007, 63, 53-64.	4.4	21
269	Once-weekly epoetin beta treatment in anemic patients with breast cancer receiving chemotherapy: Interim analysis of a multicenter, single arm study. Journal of Clinical Oncology, 2007, 25, 19605-19605.	1.6	1
270	Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Annals of Oncology, 2006, 17, 74-78.	1.2	92

#	ARTICLE	IF	CITATIONS
271	Infertility and pregnancy after breast cancer: Current knowledge and future perspectives. <i>Cancer Treatment Reviews</i> , 2006, 32, 417-422.	7.7	46
272	Safety of adjuvant aromatase inhibitor therapy. <i>Cancer Treatment Reviews</i> , 2006, 32, 548-556.	7.7	17
273	Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 45-53.	2.5	33
274	Fertility Preservation Strategies for Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 4220-4221.	1.6	9
275	Taxane-containing chemotherapy in the treatment of early breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, vii22-vii26.	1.2	10
276	HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. <i>British Journal of Cancer</i> , 2005, 93, 7-14.	6.4	37
277	Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 5117-5125.	1.6	114
278	Reply to "Weekly paclitaxel in elderly breast cancer patients", by C. Smorenburg et al. (<i>Ann Oncol</i> 2005); Tj ETQg0 0 0 rgBT /Overlo	1.2	1
279	Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer). <i>Annals of Oncology</i> , 2005, 16, 253-258.	1.2	76
280	Sequential Treatment with Exemestane and Non-Steroidal Aromatase Inhibitors in Advanced Breast Cancer. <i>Oncology</i> , 2005, 69, 471-477.	1.9	88
281	Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1724-1733.	6.3	146
282	Maintenance Hormone Therapy with Letrozole after First-Line Chemotherapy for Advanced Breast Cancer. <i>Oncology</i> , 2005, 68, 364-370.	1.9	18
283	ATAC trial update. <i>Lancet, The</i> , 2005, 365, 1225.	13.7	8
284	Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study. <i>Journal of Clinical Oncology</i> , 2005, 23, 522-522.	1.6	6
285	Temporary ovarian suppression with goserelin for prevention of chemotherapy-induced menopause in young early breast cancer patients: Results of a phase II study. <i>Journal of Clinical Oncology</i> , 2005, 23, 662-662.	1.6	3
286	Le Linee Guida Aiom per le Neoplasie Della Mammella. <i>Tumori</i> , 2004, 90, 1-8.	1.1	3
287	Sentinel lymph node biopsy in breast cancer patients: The medical oncology perspective. <i>Journal of Surgical Oncology</i> , 2004, 85, 129-132.	1.7	13
288	Weekly Paclitaxel in Elderly Patients with Advanced Breast Cancer. <i>Drugs in R and D</i> , 2004, 5, 11-15.	2.2	5

#	ARTICLE	IF	CITATIONS
289	HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy (CT) in early breast cancer (BC) patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 571-571.	1.6	3
290	Erlotinib given sequentially to capecitabine and vinorelbine as first-second line chemotherapy in metastatic breast cancer patients. A dose finding study. <i>Journal of Clinical Oncology</i> , 2004, 22, 834-834.	1.6	3
291	Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. <i>Cancer</i> , 2003, 97, 1174-1180.	4.1	23
292	Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. <i>Annals of Oncology</i> , 2003, 14, 1222-1226.	1.2	16
293	Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 280-285.	1.2	16
294	Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. <i>Annals of Oncology</i> , 2002, 13, 883-888.	1.2	82
295	Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. <i>Annals of Oncology</i> , 2002, 13, 546-552.	1.2	16
296	Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients. <i>European Journal of Cancer</i> , 2002, 38, 359-366.	2.8	37
297	Is it Possible to use Anthracyclines in Patients Older than 70 Years? <i>Contra. Tumori</i> , 2002, 88, S136-S137.	1.1	2
298	Predicting mood disorders in breast cancer patients. <i>European Journal of Cancer</i> , 2001, 37, 216-223.	2.8	69
299	Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy. <i>Oncology</i> , 2001, 60, 88-93.	1.9	9
300	Accelerated-Intensified Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Compared With Standard CEF in Metastatic Breast Cancer Patients: Results of a Multicenter, Randomized Phase III Study of the Italian Gruppo Oncologico Nord-Ouest "Mammella Inter Gruppo Group. <i>Journal of Clinical Oncology</i> , 2001, 19, 2213-2221.	1.6	41
301	Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. <i>Annals of Oncology</i> , 2001, 12, 505-508.	1.2	13
302	Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery. <i>Annals of Oncology</i> , 2001, 12, 373-378.	1.2	6
303	Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients. <i>Annals of Oncology</i> , 2001, 12, 1097-1106.	1.2	22
304	Dose-dense sequential administration and same day administration of epirubicin and paclitaxel yield similar response rates in women with advanced breast cancer. <i>Evidence-based Oncology</i> , 2001, 2, 211-213.	0.1	0
305	Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2000, 59, 133-139.	2.5	23
306	Sequence Effect of Epirubicin and Paclitaxel Treatment on Pharmacokinetics and Toxicity. <i>Journal of Clinical Oncology</i> , 2000, 18, 2116-2125.	1.6	44

#	ARTICLE	IF	CITATIONS
307	Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 1999, 17, 1132-1132.	1.6	65
308	Chemotherapy of non-small-cell lung cancer: Role of erythropoietin in the management of anemia. <i>Annals of Oncology</i> , 1999, 10, S91-S94.	1.2	21
309	Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. <i>Supportive Care in Cancer</i> , 1999, 7, 121-127.	2.2	447
310	Tamoxifen and the endometrium: findings of pelvic ultrasound examination. <i>Breast Cancer Research and Treatment</i> , 1998, 47, 41-46.	2.5	64
311	S29 Putting the taxanes to work: Open questions. <i>European Journal of Cancer</i> , 1998, 34, S7.	2.8	0
312	P29 Tumor proliferative activity evaluated with thymidine labelling index predicts response to adjuvant chemotherapy. <i>European Journal of Cancer</i> , 1998, 34, S21.	2.8	0
313	The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study. <i>Annals of Oncology</i> , 1998, 9, 187-190.	1.2	76
314	More on dose-intensity of anthracyclines in breast cancer. <i>Annals of Oncology</i> , 1998, 9, 461.	1.2	3
315	Putting the Taxanes to Work: Unanswered Questions. <i>Recent Results in Cancer Research</i> , 1998, 152, 305-313.	1.8	1
316	Strategies for the Use of Epoetin Alfa in Breast Cancer Patients. <i>Oncologist</i> , 1998, 3, 314-318.	3.7	5
317	Paradoxical Effect of Cytotoxic Chemotherapy on Anemia in Cancer Patients With \hat{A} -Thalassemia Minor. <i>Journal of the National Cancer Institute</i> , 1997, 89, 455-456.	6.3	0
318	Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.. <i>Journal of Clinical Oncology</i> , 1997, 15, 2715-2721.	1.6	118
319	Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 183-190.	2.5	116
320	Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 3112-3120.	1.6	146
321	Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 764-773.	1.6	53
322	Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 487-494.	2.3	11
323	Randomized cooperative study of perioperative chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2712-2721.	1.6	28
324	Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2851-2855.	1.6	218

#	ARTICLE	IF	CITATIONS
325	Adjuvant Chemotherapy in Breast Cancer. <i>New England Journal of Medicine</i> , 1995, 333, 596-597.	27.0	3
326	Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epirubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy. <i>Cancer</i> , 1994, 74, 2300-2306.	4.1	19
327	A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer. <i>European Journal of Cancer</i> , 1994, 30, 606-610.	2.8	18
328	Angiosarcoma of the residual breast after conservative surgery and radiotherapy for primary carcinoma. <i>Annals of Oncology</i> , 1994, 5, 163-165.	1.2	53
329	Mitomycin C and Mitoxantrone in Anthracycline-Pretreated Advanced Breast Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 218-222.	1.3	8
330	Endocrine Factors in the Outcome of Systemic Adjuvant Therapy of Early Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 330-338.	3.8	2
331	High Dose Intensity Chemotherapy without Bone Marrow Support: Role of Granulocyte-Macrophage Colony-Stimulating Factor. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 389-397.	3.8	1
332	Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. <i>British Journal of Cancer</i> , 1991, 63, 799-803.	6.4	101
333	Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 1990, 16, 111-117.	2.5	11